NewsRoom Articles - BioMedWire (BMW)

FridayOct 23, 2026 10:10 am

Peter Thiel, OpenAI Back Brain Implant Firm Targeting Cancer

Coherence Neuro, a startup making implants designed to fight brain cancer, recently raised $45 million in a Series A funding round. The round was co-led by Peter Thiel’s Founders Fund and the OpenAI Startup Fund. Other notable participants included Lux Capital, Olive Capital and 8VC. In a post, Coherence explained that the funds collected would enable the firm to conduct their first chronic human trial to test their implant as a treatment option for glioblastoma. The firm will also seek FDA designation of the implant as a breakthrough device. The company added that they would expand their tests to other…

FridayOct 23, 2026 9:00 am

Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertisements. Adaptogenics is pursuing three complementary opportunities across pharmaceutical-quality peptide supply, proprietary therapeutics and next-generation delivery technologies. Its planned supply network could generate commercial revenue while supporting therapeutic development through external manufacturing and laboratory partners. The company is targeting metabolic health, muscle preservation, mitochondrial function, recovery and healthy ageing through proprietary peptide and small-molecule therapeutics. CEO Dr. J. David Warren brings a scientific record that includes 17 issued patents, while President Antoun Nabhan brings experience spanning more than $2 billion in healthcare transactions and two Nasdaq IPO processes. Adaptogenics…

ThursdayOct 22, 2026 10:00 am

Researchers Discover That Brain Cancers Mutate Differently When Exposed to Treatment

Researchers at Yale School of Medicine have found that as brain cancers become more resistant to treatment, they develop a variety of mutations that differ from one type of brain cancer to another. This study could pave the way for developing more targeted treatments and allowing clinicians to switch from one-size-fits-all approaches to more personalized therapies. The researchers focused on oligodendrogliomas and astrocytomas, common types of gliomas that afflict humans. The team found that as these sub-categories of brain cancer become more aggressive, they develop mutations that are radically different. For a long time, scientists have worked based on the…

ThursdayOct 22, 2026 9:45 am

Durability as the New Standard in Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

Orthopedic care is increasingly focused not only on relieving symptoms, but on delivering durable outcomes that can stand up over time. That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury. Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee. Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time? That question is particularly important in cartilage repair.…

ThursdayOct 22, 2026 9:00 am

Nano-X Imaging Ltd. (NASDAQ: NNOX) Advances Its Mission to Expand Access to Medical Imaging

Nanox is working to make advanced medical imaging more accessible through digital 3D tomosynthesis technology designed to enhance visualization beyond conventional X-rays. Its Nanox.ARC platform combines imaging hardware with cloud-based infrastructure, while the company’s broader services support image interpretation and clinical workflows. By connecting image acquisition with remote radiology expertise and AI-powered analysis, Nanox aims to support healthcare providers’ imaging and interpretation workflows more efficiently. Access to medical imaging remains an important consideration for healthcare systems, particularly in underserved regions where equipment, infrastructure and trained personnel may be limited. While conventional X-rays play an essential role in diagnostic care, their…

TuesdayOct 20, 2026 10:00 am

Bangladesh’s Measles Outbreak Provides Global Cautionary Tale

Bangladesh is currently grappling with a major measles outbreak that has seen more than 200,000 suspected cases of the disease recorded in the country, so far. Of those suspected cases, 22,000 have been confirmed by laboratory tests. These statistics cover mid-March to early October, according to the World Health Organization. WHO says 1,147 fatalities due to the disease have so far been recorded in the country, and 94% of those reported deaths are of kids aged five years or less. The Bangladesh situation underscores how challenging it can be to contain a measles outbreak at a time when vaccination uptake…

TuesdayOct 20, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline

VERAXA is implementing FDA-aligned New Approach Methodologies (“NAMs”) across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The strategy supports development of the company’s BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. An ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer required about 10 mice, compared with an estimated 200 or more for comparable…

FridayOct 16, 2026 10:00 am

Experts Draw Attention to the Long-Term Effects of Measles Infections

At a time when lots of Americans have been bombarded with misinformation and disinformation about childhood vaccines and vaccination in general, it has come to light that measles infections trigger lasting vulnerabilities in the immune system that cause survivors to be susceptible to lots of other infections. For a long time, doctors have observed that when someone gets infected with measles and the condition is successfully treated, that person tends to get infected with a variety of other diseases for several years, sometimes even their entire lifetime. Measles outbreaks have even been known to be early predictors of subsequent waves…

ThursdayOct 15, 2026 10:30 am

Oncotelic Highlights PDAOAI Discovery Platform and HCC Research at Drug Discovery 2026

Scott Myers described how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research. Saran Saund presented a four-gene HCC signature associated with survival in an exploratory discovery analysis and an independent Japanese cohort. BIO REBOOT connects the platform’s research capabilities with potential funding and development support for selected projects. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (“Oncotelic”) is pursuing a development strategy that connects biomedical literature analysis with the practical work of developing therapeutics. At Drug Discovery 2026 in Burlingame, California, Scott Myers and Saran Saund showed how the company’s PDAOAI platform can help…

ThursdayOct 15, 2026 10:00 am

Experimental Vaccine Delivers Promising Results in Brain Cancer Trial

For more than two decades, no meaningful progress in the way glioblastoma is treated has been made. However, a recent clinical trial testing an experimental vaccine has shown promise by increasing the survival time of GBM patients, particularly those younger than 65 years. The study, which is yet to be peer-reviewed, was conducted through a collaboration between the Comprehensive Cancer Center at Roswell Park and a biotech firm, MimiMax. A press release announcing the results of the trial explains that patients who were given the SurVaxM shots survived longer by 2.5 months when compared to those given a placebo. For…